Adjuvant chemotherapy of breast cancer in the older patient

ONCOLOGY

Volumn 24, Issue 7, 2010, Pages

  Taylor, W Chris ^a   Muss, Hyman B ^a,b  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; ANTINEOPLASTIC AGENT; AROMATASE INHIBITOR; CAPECITABINE; CARBOPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FLUOROURACIL; METHOTREXATE; TAMOXIFEN; TRASTUZUMAB;

AGED; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER MORTALITY; CANCER PATIENT; CANCER STAGING; CANCER SURVIVAL; CARDIOTOXICITY; COGNITION; COMORBIDITY; DIABETES MELLITUS; DRUG TOLERABILITY; FOLLOW UP; HEALTH STATUS; HUMAN; KIDNEY FAILURE; LIVER DISEASE; NUTRITIONAL STATUS; PATIENT DECISION MAKING; POLYPHARMACY; QUALITY OF LIFE; REVIEW; SOCIAL SUPPORT; STROKE;

EID: 77958024649     PISSN: 08909091     EISSN: 08909091     Source Type: Journal    
DOI: None     Document Type: Review

References (49)

1. National Cancer Institute: Surveillance Epidemiology and End Results Cancer Statistics Review 19752005. Table IV-1: Female Breast Cancer (Invasive): Trends in SEER Incidence and US Mortality Using the Jpoinpoint Regression Program, 19752005 with Up to Three Joinpoints by Race and Age. Available at http://seer.cancer.gov/csr/1975-2005/results-merged/sect-04-breast.pdf. 2008. Accessed May 25, 2010.
2. Tai P, Cserni G, Van De Steene J, et al: Modeling the effect of age in T1-2 breast cancer using the SEER database. BMC Cancer 5:130, 2005.
3. Rosenberg J, Chia YL, Plevritis S: The effect of age, race, tumor size, tumor grade, and disease stage on invasive ductal breast cancer survival in the U.S. SEER database. Breast Ca Res Treat 89:47-54, 2005. (Pubitemid 40228446)
4. Yancik R, Wesley MN, Ries LA, et al: Effect of age and comorbidity in postmenopausal breast cancer patients aged 55 years and older. JAMA 285:885-892, 2001. (Pubitemid 32171549)
5. Diab SG, Elledge RM, Clark GM: Tumor characteristics and clinical outcome of elderly women with breast cancer. J Natl Cancer Inst 92:550-556, 2000. (Pubitemid 30212316)
6. Eppenberger-Castori S, Moore DH, Jr., Thor AD, et al: Age-associated biomarker profiles of human breast cancer. Int J Biochem Cell Biol 34:1318-1330, 2002. (Pubitemid 35245392)
7. Centers for Disease Prevention and Control: Table 26: Life Expectancy at birth, at 65 Years of Age, and at 75 Years of Age, by Race and Sex: United States, Selected Years 19002005. Available at http://www.cdc.gov/nchs/data/hus/ hus08.pdf#026. Accessed May 25, 2010.
8. Hebert-Croteau N, Brisson J, Latreille J, et al: Compliance with consensus recommendations for the treatment of early stage breast carcinoma in elderly women. Cancer 85:1104-1113, 1999.
9. Hebert-Croteau N, Brisson J, Latreille J, et al: Compliance with consensus recommendations for systemic therapy is associated with improved survival of women with node-negative breast cancer. J Clin Oncol 22:3685-3693, 2004. (Pubitemid 41095207)
10. Eaker S, Dickman PW, Bergkvist L, et al: Differences in management of older women influence breast cancer survival: Results from a population-based database in Sweden. PLoS Med 3(3):e25, 2006.
11. Crivellari D, Aapro M, Leonard R, et al: Breast cancer in the elderly. J Clin Oncol 25:1882-1890, 2007.
12. Wildiers H, Kunkler I, Biganzoli L, et al: Management of breast cancer in elderly individuals: recommendations of the International Society of Geriatric Oncology. Lancet Oncol 8:1101-1115, 2007. (Pubitemid 350182967)
13. Yancik R, Wesley MN, Ries LA, et al: Effect of age and comorbidity in postmenopausal breast cancer patients aged 55 years and older. JAMA 285:885-892, 2001. (Pubitemid 32171549)
14. Satariano WA, Ragland DR: The effect of comorbidity on 3-year survival of women with primary breast cancer. Ann Intern Med 120:104-110, 1994.
15. Schairer C, Mink PJ, Carroll L, et al: Probabilities of death from breast cancer and other causes among female breast cancer patients. J Natl Cancer Inst 96:1311-1321, 2004.
16. Extermann M, Hurria A: Comprehensive geriatric assessment for older patients with cancer. J Clin Oncol 25:1824-1831, 2007.
17. Maas HA, Janssen-Heijnen ML, Olde Rikkert MG, et al: Comprehensive geriatric assessment and its clinical impact in oncology. Eur J Cancer 43:2161-2169, 2007.
18. Hurria A, Gupta S, Zauderer M, et al: Developing a cancer-specific geriatric assessment: A feasibility study. Cancer 104:1998-2005, 2005.
19. Saliba D, Elliott M, Rubenstein LZ, et al: The Vulnerable Elders Survey: A tool for identifying vulnerable older people in the community. J Am Geriatr Soc 49:1691-1699, 2001. (Pubitemid 34007998)
20. Rodin MB, Mohile SG: A practical approach to geriatric assessment in oncology. J Clin Oncol 25:1936-1944, 2007.
21. Extermann M, Aapro M, Bernabei R, et al: Use of comprehensive geriatric assessment in older cancer patients: recommendations from the task force on CGA of the International Society of Geriatric Oncology (SIOG). Crit Rev Oncol Hematol 55(3):241-252, 2005. (Pubitemid 41219694)
22. Perou CM, Sorlie T, Eisen MB, et al: Molecular portraits of human breast tumours. Nature 406:747-752, 2000.
23. Winer EP, Hudis C, Burstein HJ, et al: American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: Status report 2004. J Clin Oncol 23:619-629, 2004
24. Paik S, Tang G, Shak S, et al: Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol 24:3726-3734, 2006. (Pubitemid 46622311)
25. Wittner BS, Sgroi DC, Ryan PD, et al: Analysis of the MammaPrint breast cancer assay in a predominantly postmenopausal cohort. Clin Cancer Res 14:2988-2993, 2008.
26. Giordano SH, Duan Z, Kuo YF, et al: Use and outcomes of adjuvant chemotherapy in older women with breast cancer. J Clin Oncol 24:2750-2756, 2006.
27. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials. Lancet 365:1687-1717, 2005. (Pubitemid 40719106)
28. Jones SE, Savin MA, Holmes FA, et al: Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer. J Clin Oncol 24:5381-5387, 2006. (Pubitemid 46623169)
29. Muss HB, Woolf S, Berry D, et al: Adjuvant chemotherapy in older and younger women with lymph node-positive breast cancer. JAMA 293:1073-1081, 2005.
30. Muss HB, Berry DA, Cirrincione C, et al: Toxicity of older and younger patients treated with adjuvant chemotherapy for node-positive breast cancer: The Cancer and Leukemia Group B Experience. J Clin Oncol 25:3699-3704, 2007. (Pubitemid 47372610)
31. Albain KS, Barlow W, Shak S, et al: Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal node-positive, ER-positive breast cancer (S8814, INT0100) (abstract 10). Breast Ca Res Treat 106(suppl 1):2007.
32. Dowsett M, Cuzick J, Wales C, et al: Risk of distant recurrence using Oncotype DX in postmenopausal primary breast cancer patients treated with anastrozole or tamoxifen: A TransATAC study. Cancer Res 69(Suppl):75s, 2008.
33. Romond EH, Perez EA, Bryant J, et al: Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 353:1673-1684, 2005. (Pubitemid 41464706)
34. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 353:1659-1672, 2005. (Pubitemid 41464705)
35. Telli ML, Hunt SA, Carlson RW, et al: Trastuzumab-related cardiotoxicity: calling into question the concept of reversibility. J Clin Oncol 25:3525-3533, 2007.
36. Slamon D, Eiermann W, Robert N, et al: BCIRG 006: 2nd interim analysis phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab with docetaxel, carboplatin and trastuzumab in Her2neu positive early breast cancer patients (abstract 52). Breast Ca Res Treat 100 (suppl 1): S90, 2006.
37. Early Breast Cancer Trialists Collaborative Group (EBCTCG), Clarke M, Coates AS, Darby SC, et al: Adjuvant chemotherapy in oestrogen-receptor-poor breast cancer: Patient-level meta-analysis of randomised trials. Lancet 371:29-40, 2008.
38. Berry DA, Cirrincione C, Henderson IC, et al: Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer. JAMA 295:1658-1667, 2006.
39. Muss HB, Woolf S, Berry D, et al: Adjuvant chemotherapy in older and younger women with lymph node-positive breast cancer. JAMA 293:1073-1081, 2005. (Pubitemid 40300281)
40. Muss HB, Berry DL, Cirrincione C, et al: Standard chemotherapy (CMF or AC) versus capecitabine in early-stage breast cancer (BC) patients aged 65 and older: Results of CALGB/CTSU 49907. J Clin Oncol 26(8s):5-20, 2008.
41. Jones S, Holmes FA, OShaughnessy J, et al: Docetaxel with cyclophosphamide is associated with an overall survival benefit compared with doxorubicin and cyclophosphamide: 7-year follow-up of US Oncology research trial 9735. J Clin Oncol 27:1177-1183, 2009.
42. Zambetti M, Valagussa P, Bonadonna G: Adjuvant cyclophosphamide, methotrexate and fluorouracil in node-negative and estrogen receptor-negative breast cancer. Updated results. Ann Oncol 7:481-485, 1996.
43. National Cancer Institute, Cancer Control and Population Sciences: Estimated US Cancer Prevalence Counts: Who Are Our Cancer Survivors in the US? Updated 5/2009. Available at http://dccps.nci.nih.gov/ocs/prevalence. Accessed April 15, 2010.
44. Hutchins LF, Unger JM, Crowley JJ, et al: Underrepresentation of patients 65 years of age or older in cancer-treatment trials. N Engl J Med 341:2061-2067, 1999. (Pubitemid 30035956)
45. Sateren WB, Trimble EL, Abrams J, et al: How sociodemographics, presence of oncology specialists, and hospital caner programs affect accrual to cancer treatment trials. J Clin Oncol 20:2109-2117, 2002. (Pubitemid 34408802)
46. Kimmick GG, Peterson BL, Kornblith AB, et al: Improving accrual of older persons to cancer treatment trials: A randomized trial comparing an educational intervention with standard information: CALGB 360001. J Clin Oncol 23:2201-2207, 2005.
47. Lewis JH, Kilgore ML, Goldman DP, et al: Participation of patients 65 years of age or older in cancer clinical trials. J Clin Oncol 21:1383-1389, 2003. (Pubitemid 46606420)
48. Kemeny MM, Peterson BL, Kornblith AB, et al: Barriers to clinical trial participation by older women with breast cancer. J Clin Oncol 21:2268-2275, 2003.
49. Trimble EL, Carter CL, Cain D, et al: Representation of older patients in cancer treatment trials. Cancer 74:2208-2214, 1994.